Non-alcoholic fatty liver disease (NAFLD) in different populations: A clinical and epidemiological study – sample of São José do Rio Preto

Andrade, Gabriel Costa de; Fujise, Luciana Harumi; Filho, Jaime Euclides de Santana; Oliveira, Fabiane Nunes De; Silva, Rita de Cássia Martins Alves da

doi:10.1590/1806-9282.62.03.218

Cited by 15 publications

(17 citation statements)

References 46 publications

(59 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Nevertheless, 61% of the patients with NAFLD in South America were found to have NASH, so the prevalence of NASH could range from 6% to 18%. 16,20,22,23 Rates of NAFLD and NASH are affected by different genetic factors in different populations.…”

Section: Prevalence and Incidence Of Nafldmentioning

confidence: 99%

Non-alcoholic fatty liver disease – A global public health perspective

Younossi

2019

Journal of Hepatology

1,446

1,169

View full text Add to dashboard Cite

As the epidemics of obesity and type 2 diabetes mellitus increase worldwide, the prevalence of nonalcoholic fatty liver disease (NAFLD) is increasing proportionately. The subtype of NAFLD which can be characterised as non-alcoholic steatohepatitis (NASH) is a potentially progressive liver disease that can lead to cirrhosis, hepatocellular carcinoma, liver transplantation, and death. NAFLD is also associated with extrahepatic manifestations such as chronic kidney disease, cardiovascular disease and sleep apnoea. NAFLD and NASH carry a large economic burden and create poor health-related quality of life. Despite this important burden, we are only beginning to understand its mechanisms of pathogenesis and the contribution of environmental and genetic factors to the risk of developing a progressive course of disease. Research is underway to identify appropriate non-invasive diagnostic methods and effective treatments. Although the risk of liver-related mortality is increased in patients with NAFLD and liver fibrosis stages F3 or F4, the leading cause of death is cardiovascular disease. Given the rapidly growing global burden of NAFLD and NASH, efforts must continue to find accurate non-invasive diagnostic and prognostic biomarkers, to develop effective treatments for individuals with advanced NASH and prevention methods for individuals at high risk of NAFLD and progressive liver disease.

show abstract

Section: Prevalence and Incidence Of Nafldmentioning

confidence: 99%

Non-alcoholic fatty liver disease – A global public health perspective

Younossi

2019

Journal of Hepatology

1,446

1,169

View full text Add to dashboard Cite

show abstract

“…After hepatitis C, NAFLD is the second leading cause of chronic liver disease in western countries and affects individuals of all age groups [1]. The prevalence of NAFLD is high, often because of western lifestyles, and ranges from approximately 20 % to 30 % in different populations [2,3]. NAFLD is associated with obesity, metabolic syndrome, and insulin resistance (IR) and is defined by the presence of lipid droplets in at least 5 % of hepatocytes [4,5].…”

Section: Introductionmentioning

confidence: 99%

“…type 2 diabetes mellitus, occurring in the majority of these patients [6]. The prevalence of fatty liver disease in patients with type 2 diabetes can reach as high as 75 % [2]. The mechanisms behind NAFLD are not clear, but a "two-hit hypothesis" has been proposed to clarify the relationship between NAFLD and IR.…”

Section: Introductionmentioning

confidence: 99%

The Relationship Between Liver Enzymes and Insulin Resistance in Type 2 Diabetes Patients with Nonalcoholic Fatty Liver Disease

Sheng

Che

et al. 2018

Horm Metab Res

View full text Add to dashboard Cite

Non-: alcoholic fatty liver disease (NAFLD) is prevalent worldwide, especially in patients with type 2 diabetes. Liver enzymes are the main warning signs of liver injury and insulin resistance (IR) is critical to NAFLD. This study was aimed to investigate the association between liver enzymes and insulin resistance in type 2 diabetes patients with NAFLD. Data from 212 diabetes patients with NAFLD were analyzed, including 118 males and 94 females who received care from 2014 to 2015. The patients were divided into three groups by severity (mild n=87, moderate n=89, severe n=36). All patients underwent standard clinical and laboratory examinations. Liver enzymes including alanine aminotransferase (ALT), aspartate aminotransferase (AST), and γ-glutamyl transferase (GGT) were measured, serum fasting glucose and serum fasting insulin were obtained. IR was assessed using the homeostasis model assessment insulin resistance index (HOMA-IR). Age, sex, and BMI did not significantly differ in patients (p>0.05). Compared with normal levels, elevated ALT and AST were associated with a higher HOMA-IR (p=0.0035, p=0.0096, respectively). HOMA-IR did not significantly differ (p>0.05) between patients with normal and elevated GGT. HOMA-IR increased as the levels of liver enzymes increased, and each enzyme showed a significant association with HOMA-IR (p=0.0166, p<0.0001, and p <0.0001). HOMA-IR differs between normal and elevated ALT and AST. Liver enzymes are associated with HOMA-IR in type 2 diabetes patients with NAFLD. These findings can help evaluate the degree of IR and hepatocellular steatosis in patients and prevent the progression of type 2 diabetes and NAFLD in clinical practice.

show abstract

“…3 It is a key causative factor for the development of non-alcoholic steatohepatitis. 12 Also drugs like tamoxifen with prolonged usage of more than six months in patients of breast carcinoma lead to the development of non-alcoholic fatty liver disease. [13][14][15][16] APRI score (Aspartate aminotransferase to platelet ratio index) has been considered as a non-invasive marker for the diagnosis of non-alcoholic steatohepatitis.…”

Section: Discussionmentioning

confidence: 99%

APRI score non-invasive marker of metabolic syndrome in breast carcinoma patients

Verma

Kaeley

Ahmad

et al. 2019

Clinical Epidemiology and Global Health

View full text Add to dashboard Cite

Background: Breast carcinoma is one of the commonest cancer in women accounting for major health burden worldwide. Metabolic syndrome is a known risk factor of non-alcoholic steatohepatitis (NASH) as well as breast carcinoma. APRI (Aspartate aminotransferase to platelet ratio index), a known non-invasive marker of liver fibrosis and steatohepatitis has never been studied in patients of metabolic syndrome with breast carcinoma. Breast carcinoma has various modifiable risk factors such as obesity and alcohol consumption. Hence, we compared APRI score in patients with breast carcinoma in order to establish a possible correlation. Aims and Objectives: Our primary objective was to study APRI (Aspartate aminotransferase to platelet ratio index) score in patients of breast carcinoma with and without metabolic syndrome. The secondary objective was to study APRI score in post-menopausal women with breast carcinoma. Material and Method: This prospective observational study included 151 patients of breast carcinoma, these patients were sub grouped into two, with and without metabolic syndrome and pre and post-menopausal women. Multiple demographic and biochemical parameters including APRI score were studied in these groups. The sensitivity and specificity of APRI score was calculated in these groups. Results: A total of 151 patients of breast carcinoma were included in the study group.53.64% patients with breast carcinoma had metabolic syndrome. The mean values of AST (Aspartate aminotransferase), BMI (Body mass index), FBS (Fasting blood sugar) and APRI score were significantly higher in the patients with metabolic syndrome. More than 50% patients of breast carcinoma belonged to the post-menopausal age group. Mean values of AST (aspartate aminotransferase), BMI (body mass index), FBS (fasting blood sugar) and APRI were higher in this group. The area under the receiver operating characteristics (ROC) curve of APRI score of metabolic syndrome patients was 0.93 and that of post-menopausal women was 0.82. Conclusion: APRI score can be used as a surrogate marker of metabolic syndrome in patients with breast carcinoma. It is also useful in planning preventive strategies in patients with breast carcinoma especially in postmenopausal age group. 1 Abdominal obesity (waist circumference > 35 in. in women) 2 Triglyceride > 150 mg/dl 3 HDL-c (high density lipoproteincholesterol < 50 mg/dl) 4 BP (blood pressure) > 130/85 mmHg 5 Fasting blood sugar > 110 mg/dl 3,4 One of the important cause of NAFLD (non-alcoholic fatty liver

show abstract

Non-alcoholic fatty liver disease (NAFLD) in different populations: A clinical and epidemiological study – sample of São José do Rio Preto

Cited by 15 publications

References 46 publications

Non-alcoholic fatty liver disease – A global public health perspective

Non-alcoholic fatty liver disease – A global public health perspective

The Relationship Between Liver Enzymes and Insulin Resistance in Type 2 Diabetes Patients with Nonalcoholic Fatty Liver Disease

APRI score non-invasive marker of metabolic syndrome in breast carcinoma patients

Contact Info

Product

Resources

About